Single Ascending Dose Tolerability Study of DG3173

NCT ID: NCT02217488

Last Updated: 2014-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31

Brief Summary

This clinical trial investigated the safety, tolerability and pharmacokinetic profile of DG3173 in a double-blind, randomized, placebo-controlled, single dose escalation Phase 1 study involving 72 healthy volunteers. Individuals received up to 2000 µg of DG3173 via single dose subcutaneous injection.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

DG3173

Group Type: EXPERIMENTAL

DG3173

Intervention Type: DRUG

Vehicle

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

DG3173

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ethnic origine: Caucasian
• Weight: 55-95 kg
• BMI: 19-29 kg/qm
• Medical history without clinically relevant pathologies
• Physical examination parameters and lung function without signs of clinically relevant pathologies
• Electrocardiogram recording without signs of clinically relevant pathology, in particular QTc (Bazett) <440ms
• Values for hematology, biochemistry and for coagulation tests of blood and urine within the normal range or showing no clinically relevant deviation as judged by the medical investigator (in particular normal values for ALAT, ASAT, LDH, gamma-GT, alkaline phosphatase, alpha-amylase and bilirubin)
• Having given written informed consent before any study-related activities are carried out

Exclusion Criteria

• Evidence of clinically relevant pathology or disease
• Any history of moderate or severe hypertension, hypotension or orthostatic hypotension
• Mental handicap
• Legal incapacity
• Any history of clinically important emotional and/or psychiatric illness or of any clinically important neurological disorders and/or epilepsy
• Chronic diarrhea or other chronic gastrointestinal disorders
• Acute or chronic gastro-duodenal ulcers
• Presence or history of endocrine disorders
• Presence or history of gall stone disease, presence excluded by means of upper abdominal ultrasound
• Known hypersensitivity to the study drug or constituent of the study drug
• History of any relevant allergy, especially drug and/or food allergies
• Strict vegetarian
• Regular treatment with medications during three months prior to randomization
• Receipt of any prescription or non-prescription medication, including multi-vitamin preparations within 14 days prior to drug administration and for the duration of the study
• Use of St. John´s Wort or Ginkgo Biloba (also known as Ginkgo Bilbao) within 48 hours prior to randomization
• Participation in a clinical study within 30 days prior to randomization
• Donation of blood within 60 days prior to randomization
• History of use of tobacco or nicotine-containing products within the past three months
• Any history of alcohol abuse or drug addiction
• Positive results at screen for drugs of abuse (cocaine, amphetamine/methamphetamine, tetrahydrocannbinol, opiates) or alcohol (breath test) at screening or on admission
• Positive screen results for HBsAg, anti-HCV, or anti-HIV1&2
• Consumption of abnormal quantities of coffee or tea (i.e. more than 5 cups per day [1 cup = 150 ml]
• Any disease which in the Investigator´s opinion would exclude the subject from the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

DeveloGen AG, Germany

UNKNOWN

Sponsor Role: collaborator

Aspireo Pharmaceuticals Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

DG3173-I-001

Identifier Type: -

Identifier Source: org_study_id